Novo Nordisk Takes The Plunge Into Alzheimer's With Phase III Semaglutide Trial

GLP-1 Agonist Linked To Inflammation Control

Analysis of cardiovascular studies show GLP-1 drugs are associated with a 53% reduced risk of developing Alzheimer’s disease.

Novo Nordisk
Novo Nordisk is making a calculated gamble on semaglutide working in Alzheimer's disease.

Novo Nordisk is to begin a Phase III trial in Alzheimer’s disease of oral semaglutide, the GLP-1 analogue which is currently licensed as Rybelsus for use in patients with type 2 diabetes.

The decision is a bold one given the almost 100% failure rate seen in Alzheimer’s late-stage trials over the last...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip